Cell&Gene therapy orchestration in a point-of-care production model

Join to learn more about a closed-loop supply chain in healthcare. Personalized treatments, like autologous cell therapies, are based on a concept that involves a single patient’s input, either in form of physical raw material (e.g. blood or tissue cells) or of data based on the patient’s analysis to produce a medicine specifically for this patient. A promising approach to reduce costs and production times of personalized cell & gene therapies is the point-of-care production model. It excludes the need to freeze and thaw the materials as well as the need to transport at all. Cell&Gene Therapies have the power to irretrievably transform today’s research and care models and hold great potential within the field of healthcare. Speakers: Jeroen Voorham, CellPoint Marten Neubauer, Healthcare Field Director, Germany, Dell Technologies Andreas Göbel, Managing Director, Hypertrust Patient Data Care